Provided by Tiger Trade Technology Pte. Ltd.

Mirum Pharmaceuticals, Inc.

100.61
+2.312.35%
Pre-market: 101.340.7300+0.73%04:00 EDT
Volume:587.04K
Turnover:58.50M
Market Cap:6.53B
PE:-7.15
High:101.18
Open:98.30
Low:97.48
Close:98.30
52wk High:130.00
52wk Low:63.23
Shares:64.93M
Float Shares:56.42M
Volume Ratio:1.19
T/O Rate:1.04%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-14.0800
EPS(LYR):-0.4700
ROE:-702.97%
ROA:-6.79%
PB:-626.83
PE(LYR):-214.06

Loading ...

Mirum Pharmaceuticals Inc : JP Morgan Raises Target Price to $125 from $115

THOMSON REUTERS
·
Jul 02

Mirum SVP, Global Controller Jolanda Howe sells 2,594 shares for $264,458.3

Reuters
·
Jun 19

Mirum Pharmaceuticals holds annual shareholder meeting

Reuters
·
Jun 19

Mirum Pharmaceuticals Is Maintained at Market Outperform by Citizens

Dow Jones
·
Jun 15

Mirum Pharmaceuticals price target raised to $146 from $140 at Citizens

TIPRANKS
·
Jun 15

Mirum Pharmaceuticals, Incyte Say Zilurgisertib Showed Meaningful Reductions in Heterotopic Ossification Lesion Volume During Clinical Trial

MT Newswires Live
·
Jun 15

Incyte, Mirum announces Phase 2 results from Cohort 1 of Progress study

TIPRANKS
·
Jun 15

Mirum, Incyte report pivotal Phase 2 PROGRESS data showing zilurgisertib cuts new FOP bone lesion volume 99.9% at Week 24

Reuters
·
Jun 15

Mirum Pharmaceuticals and Incyte Announce Positive Pivotal Phase 2 Results From Progress Study of Zilurgisertib in Fibrodysplasia Ossificans Progressiva

THOMSON REUTERS
·
Jun 15

Mirum grants inducement equity awards to 8 new hires, sets options at $94 per share

Reuters
·
Jun 12

Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)

THOMSON REUTERS
·
Jun 12

Mirum Pharmaceuticals Is Maintained at Overweight by Morgan Stanley

Dow Jones
·
Jun 11

Mirum Pharmaceuticals price target raised to $150 from $140 at Morgan Stanley

TIPRANKS
·
Jun 11

Mirum CFO Eric Bjerkholt disposes of common shares worth $468,720.88

Reuters
·
Jun 10

Incyte, Mirum Pharmaceuticals to Present New Zilurgisertib Study Results at Conference

MT Newswires Live
·
Jun 04

Incyte, Mirum to present Phase 2 results from PROGRESS study at ENDO 2026

TIPRANKS
·
Jun 04

Mirum CEO Christopher Peetz disposes of USD 2.88 million in common shares

Reuters
·
Jun 03

Mirum Pharma director Saira Ramasastry disposes of 3,977 common shares for $397,700

Reuters
·
Jun 03

Mirum Pharmaceuticals Initiated at Buy by Citigroup

Dow Jones
·
Jun 02

Mirum Pharmaceuticals Inc : Citigroup Initiates Coverage With Buy Rating; Price Target $145

THOMSON REUTERS
·
Jun 02